What targeted therapies are available for Esophageal Cancer

Targeted Therapies for Esophageal Cancer

Targeted therapies are medications designed to attack specific characteristics of cancer cells, rather than harming all rapidly dividing cells like traditional chemotherapy does. For esophageal cancer, the available targeted options depend on what biomarkers (specific features) your cancer has.

Key Biomarkers That Guide Treatment Selection

According to the NCCN Guidelines for Esophageal and Esophagogastric Junction Cancers, doctors test for specific markers to determine which targeted therapies may work:

HER2 Status (Most Important for Adenocarcinoma)

• HER2-positive adenocarcinoma: If your cancer overexpresses HER2 (a growth-promoting protein), trastuzumab (Herceptin) is added to first-line chemotherapy. This is a monoclonal antibody that blocks HER2 signaling and is FDA-approved for this indication.
• This applies to adenocarcinomas of the esophagus and esophagogastric junction

PD-L1 Status (Immunotherapy Marker)

• PD-L1 CPS ≥1: If your tumor shows PD-L1 expression (a checkpoint protein), checkpoint inhibitors are added to first-line chemotherapy
• Tislelizumab (an anti-PD-1 checkpoint inhibitor) combined with chemotherapy is FDA-approved for both:
  • Advanced esophageal adenocarcinoma
  • Advanced esophageal squamous cell carcinoma
• Other checkpoint inhibitors may be considered based on your specific situation

MSI-H/dMMR Status (Rare but Important)

• MSI-high (MSI-H) or mismatch repair deficient (dMMR) tumors: According to NCCN Guidelines, perioperative immunotherapy should be considered in consultation with your multidisciplinary team, as these tumors respond differently to treatment

How These Therapies Work

Trastuzumab blocks the HER2 protein on cancer cell surfaces, preventing growth signals and helping your immune system recognize cancer cells.

Checkpoint inhibitors like tislelizumab remove the "brakes" that cancer cells use to hide from your immune system, allowing your body's T-cells to attack the tumor more effectively.

Treatment Approach: Combination Therapy

According to NCCN Guidelines, targeted therapies are not used alone for advanced esophageal cancer. Instead, they're combined with chemotherapy regimens. The NCCN emphasizes that:

• Two-drug cytotoxic regimens are preferred for patients with advanced disease because of lower toxicity
• Trastuzumab is added to first-line chemotherapy for HER2-positive adenocarcinoma
• Checkpoint inhibitors are added to first-line chemotherapy for PD-L1 positive tumors

Important Questions to Ask Your Oncologist

1. Has my tumor been tested for HER2 status? If not, why not, and can it be tested?
2. What is my PD-L1 CPS score, and what does it mean for my treatment options?
3. Has my tumor been tested for MSI-H/dMMR status?
4. Based on my specific biomarkers, which targeted therapy combination do you recommend?
5. What are the expected side effects of the targeted therapy you're recommending, and how will we monitor for them?
6. Are there clinical trials available that might offer additional targeted therapy options?

Current Treatment Landscape

The NCCN Guidelines (Version 4.2025) note that systemic therapy regimens for advanced esophageal adenocarcinoma, esophagogastric junction adenocarcinoma, and gastric adenocarcinoma may be used interchangeably, while regimens for squamous cell carcinoma are considered separately due to different biology.

Important reminder: Your oncologist will determine which targeted therapies are appropriate for YOUR specific cancer based on your complete clinical picture, including tumor stage, your overall health, and your biomarker results. The choice between options involves weighing efficacy against potential side effects and your personal treatment goals.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.